CN117859898A - Application of ergothioneine in preparation of iron absorption promoter and iron absorption promoter - Google Patents

Abstract

The present invention relates to the technical field of food and health products, and provides the application of thioneine in preparing an iron absorption accelerator and a kind of iron absorption accelerator. The present invention proposes that a certain amount of thioneine can be supplemented while supplementing iron agent, and can significantly promote intestinal iron bioavailability, and it is confirmed by cell experiment that thioneine can promote the absorption of iron by Caco 2 cells, and suppress the expression of hepcidin, so as to promote the absorption of iron in the intestinal tract. Based on this, the present invention also proposes a kind of iron absorption accelerator, including thioneine and iron agent, and the thioneine and the iron agent can be divided into two doses, or can be mixed uniformly, and the effect of thioneine promoting the absorption of iron agent in the intestinal tract can be played.

Description

Application of ergothioneine in preparation of iron absorption enhancer and iron absorption enhancer

Technical Field

The invention relates to the technical field of food and health products, and in particular to application of ergothioneine in preparing an iron absorption accelerator and an iron absorption accelerator.

Background technique

Iron is an essential element for life. It plays an important role in many cellular processes, including energy production, oxygen transport, DNA synthesis, and many other important metabolic processes involving iron-containing enzymes. Although iron is the second most abundant metal in the earth's crust, iron deficiency is the most common cause of anemia in the world. Special populations have a great demand for iron, such as pregnant women, infants, and adolescents. When the body's iron intake is inefficient, iron deficiency can easily occur. Iron deficiency can lead to a series of health problems, including insufficient qi and blood, cold hands and feet, restless legs syndrome, affecting brain development, and even life-threatening in severe cases.

Most of the iron absorbed in the body comes from the diet. Food contains two types of iron, including heme and non-heme. Heme iron is only found in animal products, such as meat, fish and poultry, while non-heme iron is found in fruits, vegetables, dry beans, nuts, grain products and meat. Heme iron is absorbed more efficiently from the intestine than non-heme iron. Non-heme iron is mainly trivalent iron, which will form precipitation in an environment with a pH value higher than 3. Only divalent iron can be absorbed by enterocytes in the intestine and enter the circulation. Iron absorption and metabolism are controlled by a key regulatory substance, hepcidin, which is considered to be a negative regulator that inhibits intestinal iron absorption and reticuloendothelial cell iron release. It is mainly synthesized in the liver. During iron overload and inflammation, its expression is enhanced, downregulating the expression of ferroportin and reducing the body's absorption of iron. When the body is iron deficient, the above process changes in the opposite way to maintain iron homeostasis. Hepcidin, as a negative iron regulatory hormone, can itself become an exogenous drug that reduces the body's iron level to treat iron overload diseases. Conversely, some hepcidin inhibitors or blockers are also useful in the treatment of chronic inflammatory anemia, iron deficiency anemia, etc.

Ergothioneine (EGT) is a highly effective antioxidant that can effectively scavenge free radicals and reduce oxidative stress levels. Although it cannot be synthesized by the human body, it has a specific transporter in mammals - the novel organic cation transporter 1 (OCTN-1), which is highly expressed in most tissues and organs of mammals, especially the eyes, liver, kidneys, heart, skin, etc. A large number of studies have found that this antioxidant ingredient, in addition to its job of scavenging free radicals, can also effectively regulate the activity and expression of various physiological regulatory molecules, such as upregulating the expression of the longevity protein Sirtuin, upregulating the energy metabolism-related protein PGC1-α, downregulating the expression of tyrosinase and inhibiting its activity, downregulating the expression of metal matrix protease MMP and inhibiting its activity, etc. Therefore, EGT can be used as a multifunctional nutrient to participate in various biochemical reactions and effectively play an anti-aging and health-care role.

Summary of the invention

The present invention aims to provide an application of ergothioneine in promoting iron absorption.

The first aspect of the present invention provides the use of ergothioneine in preparing an iron absorption enhancer.

Specifically, in the application provided by the present invention, the ergothioneine promotes the absorption of iron in the intestine by promoting the absorption of iron by Caco-2 cells.

Specifically, in the application provided by the present invention, the ergothioneine also promotes the absorption of iron in the intestine by inhibiting the expression of hepcidin.

A second aspect of the present invention provides an iron absorption promoter, which comprises ergothioneine and an iron agent, wherein the ergothioneine promotes the absorption of the iron agent in the intestine.

Optionally, the iron absorption enhancer provided by the present invention comprises a first dose and a second dose, wherein the first dose comprises ergothioneine, and the second dose comprises an iron agent.

Optionally, in the iron absorption enhancer provided by the present invention, the ergothioneine and the iron agent are mixed uniformly.

Optionally, in the iron absorption enhancer provided by the present invention, the ergothioneine is administered orally or by injection, and the dosage of the ergothioneine is 5 to 30 mg/day.

A third aspect of the present invention provides the application that ergothioneine promotes iron absorption, and this kind of application can be the application of therapeutic purpose, and can also be the application of non-therapeutic purpose.Alternatively, the application provided by the present invention is the application of non-therapeutic purpose.

Relative to prior art, the present invention proposes that a certain amount of thioneine can be supplemented while supplementing iron agent and can significantly promote intestinal iron bioavailability, and confirms that thioneine can promote the absorption of iron by Caco-2 cells by cell experiments, and suppresses the expression of hepcidin, so as to promote the absorption of iron in the intestinal tract. Based on this, the present invention also proposes a kind of iron absorption promoter, including thioneine and iron agent, and the thioneine and the iron agent can be divided into two doses, or can be mixed uniformly, and the effect of thioneine promoting the absorption of iron agent in the intestinal tract can be played.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG1 is a comparison of Fe content in Caco-2 cells of various experimental groups in Example 1;

FIG. 2 is a graph comparing the expression levels of hepcidin in HepG2 cells of each experimental group in Example 2.

Detailed ways

In order to make the purpose, technical scheme and advantages of the present invention clearer, each embodiment of the present invention will be described in detail below. However, it will be appreciated by those skilled in the art that in each embodiment of the present invention, many technical details are provided to enable the reader to better understand the present application. However, even without these technical details and various changes and modifications based on the following embodiments, the technical scheme claimed in the present application can be implemented.

All raw materials in the embodiment of the present invention are commercially available products: wherein the used ergothioneine (EGT): properties: white powder, purity:> 99%.

Example 1 Caco-2 cell model experiment

The Caco-2 cell model is a human cloned colon adenocarcinoma cell line with a structure and function similar to differentiated intestinal epithelial cells. It has structures such as microvilli and contains enzyme systems related to the brush border epithelium of the small intestine. It can be used to conduct experiments simulating intestinal transit in vivo.

1. Caco-2 cell culture

Caco-2 cells were seeded in 6-well plates and maintained in normal growth medium for 10 days. Four experimental groups were set up, namely blank control group (Blank), EGT 0.1mM group, EGT 1.0mM group, and EGT 10mM group. The EGT 0.1mM group, EGT 1.0mM group, and EGT10mM group were treated with 0.1mM, 1.0mM, and 10mM EGT concentrations for 24 hours, respectively. The blank control group was treated with normal medium without EGT for the same time, and then FeSO ₄ and iron ammonium citrate were added for incubation for 12 hours. The final concentration of both iron compounds was 10μmol/L.

2. Determination of Fe content

After the culture was completed, the cells were washed, the cells were broken and the contents were collected, and the relative Fe content in the cells was determined by flame atomic absorption spectrometry (FAAS).

3. Test results

Figure 1 is a comparison of the Fe content in the Caco-2 cells of each experimental group in Example 1; where, compared with the blank control group, * indicates p < 0.05, and ** indicates p < 0.01. As shown in Figure 1, the Fe content in the Caco-2 cells incubated with EGT increased/significantly increased relative to the Fe content in the Caco-2 cells incubated without EGT, indicating that EGT can promote the absorption of iron by Caco-2 cells.

Example 2 HepG2 cell model experiment

HepG2 cells are a type of liver cancer cell that secrete a variety of plasma proteins: albumin, α2-macroglobulin, plasminogen, iron transfer protein, etc., and are often used in the study of various liver-synthesized proteins.

1. HepG2 cell culture

HepG2 cells were seeded in 6-well plates and maintained in normal growth medium for 4 days. Four experimental groups were set up, namely blank control group (Blank), EGT 0.1mM group, EGT 1.0mM group, and EGT 10mM group. The EGT 0.1mM group, EGT 1.0mM group, and EGT10mM group were treated with 0.1mM, 1.0mM, and 10mM EGT for 6 hours, respectively, while the blank control group was treated with normal medium without EGT for the same period of time.

2. Determination of Hepcidin Expression Level

After the culture, total RNA was extracted and reverse transcribed into complementary DNA (cDNA). 1 μL cDNA suspension was used for semi-quantitative and real-time PCR detection of hepcidin expression.

3. Test results

Figure 2 is a comparison of the expression levels of hepcidin in HepG2 cells in each experimental group in Example 2; where * indicates p < 0.05 compared with the blank control group. As can be seen from Figure 2, the expression level of Hepcidin in HepG2 cells incubated with EGT was reduced/significantly reduced relative to the expression level of Hepcidin in HepG2 cells incubated without EGT, indicating that EGT inhibits the expression of hepcidin, thereby promoting the absorption of iron in the intestine.

Based on the above examples 1 to 2, embodiments of the present invention propose that thioneine can promote iron absorption, and this application can be an application for therapeutic purposes or an application for non-therapeutic purposes. Optionally, the application provided by some embodiments of the present invention is an application for non-therapeutic purposes. Ergothioneine can also be used to prepare an iron absorption enhancer. Specifically, thioneine can promote the absorption of iron by Caco-2 cells and inhibit the expression of hepcidin, thereby promoting the absorption of iron in the intestinal tract.

Embodiments of the present invention also provide an iron absorption promoter, the promoter comprises ergothioneine and an iron agent, and the ergothioneine promotes the absorption of the iron agent in the intestinal tract. In some embodiments, the iron absorption promoter comprises a first dose and a second dose, the first dose comprises ergothioneine, and the second dose comprises an iron agent. In some embodiments, the ergothioneine and the iron agent in the iron absorption promoter are mixed uniformly. In some embodiments of the present invention, the ergothioneine in the iron absorption promoter is administered orally or by injection, and the dosage of the ergothioneine is 5 to 30 mg/day.

Those skilled in the art will appreciate that the above-mentioned embodiments are specific examples for implementing the present invention, and in actual applications, various changes may be made thereto in form and detail without departing from the spirit and scope of the present invention.

Claims (8)

1. Application of ergothioneine in the preparation of iron absorption enhancers. 2. application according to claim 1, is characterized in that, described ergothioneine promotes the absorption of iron by Caco-2 cells, thereby promoting the absorption of iron in intestinal tract. 3. application according to claim 1, is characterized in that, described ergothioneine suppresses the expression of hepcidin, thereby promotes the absorption of iron in the intestinal tract. 4. an iron absorption accelerator, is characterized in that, comprises thioneine and iron agent, and described thioneine promotes the absorption of described iron agent in intestinal tract. 5. according to right want the iron absorption promoter described in 4, it is characterized in that described iron absorption promoter comprises a first dose and a second dose, and described first dose comprises described ergothioneine, and described second dose comprises described iron agent. 6. iron absorption enhancer according to claim 4, is characterized in that, in described iron absorption enhancer, described ergothioneine and described iron agent are mixed homogeneously. 7. The iron absorption enhancer according to claim 4, characterized in that, in the iron absorption enhancer, the ergothioneine is administered orally or by injection, and the dosage of the ergothioneine is 5 to 30 mg/day. 8. Use of ergothioneine to promote iron absorption, optionally, the use is for non-therapeutic purposes.